FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070403944> ?p ?o ?g. }

• W2070403944 endingPage "880" @default.
• W2070403944 startingPage "859" @default.
• W2070403944 abstract ": Purpose: Gabapentin (GBP), lamotrigine (LTG), tiagabine (TGB), topiramate (TPM), vigabatrin (VGB), and zonisamide (ZNS) are all in use as “add-on” treatment for patients with refractory epilepsy. There have been no comparative randomized controlled trials allowing an evidence-based choice between these drugs. We report a series of meta-analyses of randomized placebo-controlled add-on trials in which these drugs have been tested in patients with partial epilepsy. This work provides an estimate of each drug's efficacy and tolerability compared with placebo. These estimates are compared across drugs to give broad estimates of comparative efficacy and tolerability. Methods: Trial reports were found by searching Medline, by searching through journals by hand, and by contacting the pharmaceutical industry. The outcomes chosen were the proportion of patients who (a) have a 350% reduction in seizure frequency (50% responders); (b) withdrew from the study (any reason); or (c) reported the following side effects: ataxia, dizziness, fatigue, nausea, or somnolence. Overall odds ratio (OR) with 95% confidence intervals (CIS; 50% responders) or 99% CIS; side effects) were calculated. Results: Twenty-nine trials were included, representing 4,091 randomized patients. The ORs for 50% response (95% CI) were GBP, 2.29 (1.53–3.43); LTG, 2.32 (1.47–3.68); TGB, 3.03 (2.01–4.58); TPM, 4.07 (2.87–5.78); VGB, 3.67 (2.44–5.51); and ZNS, 2.7 (1.36–4.47). ORs for discontinuation were GBP, 1.36 (0.75–2.49); LTG, 1.19 (0.79–1.79); TGB, 1.81 (1.21–2.70); TPM, 2.56 (1.64–4.00); VGB, 2.58 (126–5.27); and ZNS, 4.23 (1.71–10.49). Conclusions: We have clear evidence that each of these drugs is better than placebo at preventing seizures. When results are compared across drugs, the confidence intervals overlap, and we have no conclusive evidence of differences in efficacy or tolerability. Despite this, the agent that appears most effective may be twice as effective as the agent that appears least effective, and the agent that appears most likely to cause discontinuation may be 4 times more likely to do so than the treatment that appears least likely to do so. Comparative randomized studies are needed further to evaluate these drugs." @default.
• W2070403944 created "2016-06-24" @default.
• W2070403944 creator A5005069325 @default.
• W2070403944 creator A5018167841 @default.
• W2070403944 creator A5048642442 @default.
• W2070403944 creator A5081969377 @default.
• W2070403944 date "1997-08-01" @default.
• W2070403944 modified "2023-10-18" @default.
• W2070403944 title "The New Antiepileptic Drugs: A Systematic Review of Their Efficacy and Tolerability" @default.
• W2070403944 cites W1974098973 @default.
• W2070403944 cites W1976810263 @default.
• W2070403944 cites W1981581965 @default.
• W2070403944 cites W1989338639 @default.
• W2070403944 cites W1989340210 @default.
• W2070403944 cites W1992469827 @default.
• W2070403944 cites W1995716893 @default.
• W2070403944 cites W1999374340 @default.
• W2070403944 cites W2016679698 @default.
• W2070403944 cites W2022532249 @default.
• W2070403944 cites W2033830039 @default.
• W2070403944 cites W2039674635 @default.
• W2070403944 cites W2043354111 @default.
• W2070403944 cites W2053593571 @default.
• W2070403944 cites W2054424230 @default.
• W2070403944 cites W2060417951 @default.
• W2070403944 cites W2079603415 @default.
• W2070403944 cites W2088440043 @default.
• W2070403944 cites W2095383648 @default.
• W2070403944 cites W2116547322 @default.
• W2070403944 cites W2124279185 @default.
• W2070403944 cites W2139593954 @default.
• W2070403944 cites W2139617051 @default.
• W2070403944 cites W2158638175 @default.
• W2070403944 cites W2161147823 @default.
• W2070403944 cites W2161242462 @default.
• W2070403944 cites W2300163045 @default.
• W2070403944 cites W2320058521 @default.
• W2070403944 cites W4239471829 @default.
• W2070403944 cites W4246783752 @default.
• W2070403944 cites W4247231670 @default.
• W2070403944 cites W4301861531 @default.
• W2070403944 doi "https://doi.org/10.1111/j.1528-1157.1997.tb01251.x" @default.
• W2070403944 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9579887" @default.
• W2070403944 hasPublicationYear "1997" @default.
• W2070403944 type Work @default.
• W2070403944 sameAs 2070403944 @default.
• W2070403944 citedByCount "314" @default.
• W2070403944 countsByYear W20704039442012 @default.
• W2070403944 countsByYear W20704039442013 @default.
• W2070403944 countsByYear W20704039442014 @default.
• W2070403944 countsByYear W20704039442015 @default.
• W2070403944 countsByYear W20704039442016 @default.
• W2070403944 countsByYear W20704039442017 @default.
• W2070403944 countsByYear W20704039442018 @default.
• W2070403944 countsByYear W20704039442019 @default.
• W2070403944 countsByYear W20704039442020 @default.
• W2070403944 countsByYear W20704039442021 @default.
• W2070403944 countsByYear W20704039442023 @default.
• W2070403944 crossrefType "journal-article" @default.
• W2070403944 hasAuthorship W2070403944A5005069325 @default.
• W2070403944 hasAuthorship W2070403944A5018167841 @default.
• W2070403944 hasAuthorship W2070403944A5048642442 @default.
• W2070403944 hasAuthorship W2070403944A5081969377 @default.
• W2070403944 hasBestOaLocation W20704039441 @default.
• W2070403944 hasConcept C118552586 @default.
• W2070403944 hasConcept C126322002 @default.
• W2070403944 hasConcept C142724271 @default.
• W2070403944 hasConcept C168563851 @default.
• W2070403944 hasConcept C197934379 @default.
• W2070403944 hasConcept C204787440 @default.
• W2070403944 hasConcept C27081682 @default.
• W2070403944 hasConcept C2775858608 @default.
• W2070403944 hasConcept C2776608144 @default.
• W2070403944 hasConcept C2776749334 @default.
• W2070403944 hasConcept C2777138316 @default.
• W2070403944 hasConcept C2777683783 @default.
• W2070403944 hasConcept C2778186239 @default.
• W2070403944 hasConcept C2778375690 @default.
• W2070403944 hasConcept C2778715236 @default.
• W2070403944 hasConcept C2778802184 @default.
• W2070403944 hasConcept C2780580376 @default.
• W2070403944 hasConcept C2780837902 @default.
• W2070403944 hasConcept C42219234 @default.
• W2070403944 hasConcept C71924100 @default.
• W2070403944 hasConceptScore W2070403944C118552586 @default.
• W2070403944 hasConceptScore W2070403944C126322002 @default.
• W2070403944 hasConceptScore W2070403944C142724271 @default.
• W2070403944 hasConceptScore W2070403944C168563851 @default.
• W2070403944 hasConceptScore W2070403944C197934379 @default.
• W2070403944 hasConceptScore W2070403944C204787440 @default.
• W2070403944 hasConceptScore W2070403944C27081682 @default.
• W2070403944 hasConceptScore W2070403944C2775858608 @default.
• W2070403944 hasConceptScore W2070403944C2776608144 @default.
• W2070403944 hasConceptScore W2070403944C2776749334 @default.
• W2070403944 hasConceptScore W2070403944C2777138316 @default.
• W2070403944 hasConceptScore W2070403944C2777683783 @default.
• W2070403944 hasConceptScore W2070403944C2778186239 @default.
• W2070403944 hasConceptScore W2070403944C2778375690 @default.

• next